Pfizer shares have gained ground since a report over the weekend said that activist investor Starboard Value has taken a roughly $1 billion stake in the drug maker and is pushing for changes. Monitor ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...

Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...

Wall Street's major indexes closed down around 1% as rising Treasury yields and Middle East tensions weighed on the market.

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

With one headline, Pfizer had gone from being a well-known hunter — spending heavily to buy rivals — to the hunted.

Financial leaders are forgoing the biggest climate conference on the calendar, and Spain has a plan to make it easier for companies within the European Union to raise money. Plus, Boeing is dealing ...

Escalating geopolitical tensions in the Middle East are also hurting investor appetite. The CBOE Volatility index, Wall ...

Activist investor Starboard Value has taken a stake of about US$1bil in Pfizer Inc and is seeking to spur a turnaround of the ...

has been a mixed bag for energy stocks, with economic concerns, geopolitical risk and volatile oil prices, but some oil and gas stocks have outperformed the rest of the market.

Since 2011, Starboard Value's Jeff Smith has extracted board seats and profits from corporate America — by force if necessary ...